Original Article
Split Viewer
Blood Res 2016; 51(3):
Published online September 23, 2016
https://doi.org/10.5045/br.2016.51.3.200
© The Korean Society of Hematology
Changes in serum uric acid levels after allogeneic hematologic stem cell transplantation: A retrospective cohort study
1Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
2Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Medical Research Institute, Seoul National University, Seoul, Korea.
3Division of Hematology and Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
4Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
5Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
Correspondence to : Correspondence to Sung-Soo Yoon, M.D., Ph.D. Division of Hematology/Oncology, Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Clinical Research Institute, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul 03080, Korea. ssysmc@snu.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background
Since cell turnover in the hematopoietic system constitutes a major source of uric acid (UA) production, we investigated whether hematopoietic stem cell transplantation (HSCT) is associated with significant changes in serum UA levels in patients with hematological disorders.
Methods
Patients who underwent HSCT at our institution between 2001 and 2012 were retrospectively enrolled. Serum UA levels at 3 months before, 1 week before, and 3 months and 1 year after HSCT were examined.
Results
Complete clinical and laboratory information including data regarding UA levels was available for 93 patients. At baseline, the mean UA level was 4.9±2.1 mg/dL, with an overall prevalence of hyperuricemia of 15% (defined as serum UA>6.8 mg/dL). Mean UA levels tended to be higher in patients with acute myeloid leukemia (4.8±2.0 mg/dL) and non-Hodgkin lymphoma (5.1±2.3 mg/dL) and lower in patients with aplastic anemia (mean, 4.2±1.8 mg/dL). UA levels dropped during myeloablative conditioning, reaching a nadir on the day of HSCT (3.27±1.4 mg/dL). Over the 3 months following HSCT, UA levels rose sharply (5.0±2.1 mg/dL) and remained stable up to 1 year after HSCT (5.5±1.6 mg/dL). UA levels in HSCT recipients at 12 months correlated with those of their respective graft donors (Pearson r=0.406,
Conclusion
HSCT is associated with significant changes in uric acid levels in patients with hematologic disorders.
Keywords Uric acid, Hematopoietic stem cell transplantation, Bone marrow
INTRODUCTION
Degradation of purine nucleotides during cell turnover contributes to endogenous production of uric acid (UA). Constant turnover of hematopoietic cells constitutes a major site of purine salvage and metabolism [1]. With normal UA removal by the kidney, serum UA levels should correlate with cell turnover in the hematopoietic system. Accordingly, pathologically accelerated cell turnover in patients with hematologic malignancies would increase the delivery of purines to the liver where hepatic xanthine oxidase metabolizes them into UA, resulting in increased serum UA levels. Indeed, elevated UA levels in patients with acute myeloid leukemia (AML) are predictive of a poor outcome [2,3]. Conversely, a reduced cell turnover in bone marrow (BM) is associated with lower serum UA levels [4,5].
Successful hematopoietic stem cell transplantation (HSCT) restores blood cell turnover in BM. HSCT with associated radical changes may significantly affect serum UA levels and may even normalize levels in patients with hematological diseases. To date, the long-term effects of HSCT on serum UA levels have not been fully elucidated [6]. In this study, we aimed to investigate the changes in UA levels over time in patients who underwent allogeneic HSCT.
MATERIALS AND METHODS
The medical records of 292 patients who underwent allogeneic HSCT at Seoul National University Hospital between 2001 and 2012 were reviewed. Baseline clinical characteristics, BM pathology, karyotypes, and serum UA levels were ascertained by reviewing the electronic medical records. Within 1 year of HSCT, 117 patients died. Major causes of death were septic shock (N=42, 35.9%), graft-versus-host disease (N=25, 21.4%), and infection (N=19, 16.2%). Therefore, a comprehensive medical record was available in 93 patients (Fig. 1). Serum UA levels at day 90±14 before HSCT, on the day of transplantation, and at days 90±14 and 365±14 post-HSCT were examined. Of note, per the HSCT protocol at our institution, all patients received allopurinol 300 mg daily during myeloablative conditioning (i.e., 7 days before HSCT) as prophylaxis for tumor lysis syndrome. Patients also received cyclosporine as prophylaxis for graft-versus-host disease.
The study was approved by the Institutional Review Board of Seoul National University Hospital. Obtaining informed consent was waived by the Review Board as the study involved minimal risk and no identifiable information was used.
Data were expressed as mean±SD for continuous variables and percentages for categorical variables. Student's t-tests or the Mann-Whitney test for continuous variables was performed as appropriate. The changes in UA levels over time were evaluated using repeated measure analysis of variance (ANOVA). The correlation between recipient UA levels at 1 year after HSCT and donor UA levels were evaluated using Pearson's correlation.
Baseline characteristics of patients who underwent HSCT (N=93) are reported in Table 1. The mean age was 40.5±11.6 years. Acute myeloid leukemia (N=23) was the most common reason for HSCT, followed by severe aplastic anemia (N=15), acute lymphoblastic leukemia (N=15), and chronic myeloid leukemia (N=15). No patient had a prior history of gout.
The mean baseline UA level was 4.9±2.1 mg/dL. Similar baseline UA levels were observed in aplastic anemia patients (mean, 4.2±1.8 mg/dL). Mean UA levels tended to be higher in patients with chronic myeloid leukemia (6.4±2.0 mg/dL) and non-Hodgkin lymphoma (NHL, 5.1±2.3 mg/dL) (Fig. 2A). UA levels dropped significantly during myeloablative conditioning, reaching a nadir on the day of HSCT (3.3±1.4,
For 89 patients, UA levels of their respective hematopoietic stem cell donors were available. The UA levels in patients at 12 months after HSCT correlated significantly with those of their respective graft donors (Pearson's r=0.406,
To the best of our knowledge, this is the first report to demonstrate the changes in UA levels over time in patients who underwent allogeneic HSCT. Since the cell turnover in BM is a major contributor to endogenous production of UA, serum UA levels should closely correlate with cell turnover in the hematopoietic system. Indeed, baseline UA levels appeared to reflect cell turnover rate within and outside BM in patients with hematological diseases, with the lowest UA levels observed in patients with aplastic anemia and the highest in those with chronic myeloid leukemia (Fig. 2A). Higher UA levels might reflect increased pathological cell turnover; in fact, increased UA levels have been shown to be associated with a worse outcome in acute myeloid leukemia [3]. Conversely, lower UA levels might be associated with disease activity or a worse outcome in patients with aplastic anemia, which is characterized by hypocellular and possibly hypoactive BM. Accordingly, restoration of normal cell turnover after HSCT tended to normalize the serum UA levels; both elevated and decreased UA levels in recipients normalized at 1 year after HSCT (Fig. 2C). Of note, 235 (80.5%) of 292 patients underwent a follow-up BM study. Of those, 30 (12.8%) exhibited hypoplasia or aplasia, whereas 157 (66.8%) had normal BM. Disease recurred in 48 (20.4%) patients. UA levels tended to be different between patients with hypoplastic or aplastic BM (4.31±1.92 mg/dL), normal BM (4.76±2.13 mg/dL), and disease recurrence in BM (5.01±3.82 mg/dL) (data not shown). As to whether normalization of the serum UA level is a useful biomarker of successful long term engrafting needs to be investigated in a larger prospective cohort.
It is conceivable that the rate of cell turnover in the hematopoietic system varies around a preset individual baseline, depending on cell demand in the periphery [7]. HSCT replaces recipient BM cells with donor cells, and would reset the intrinsic cell turnover rate of the recipient to that of the donor. Indeed, UA levels of recipients correlated significantly with the baseline UA levels of the respective donors (Fig. 3).
This retrospective study has several limitations. The cell turnover in the hematopoietic system is only one of many factors contributing to serum UA levels [7,8]. UA levels are substantially influenced by the daily dietary intake, renal excretion, and concomitant medications that might influence cell turnover and renal function. As an example, a common immune suppressant, cyclosporine, which is routinely used to prevent graft-versus-host disease, can impair renal function and thus increase UA levels [8,9,10]. However, as UA levels of each patient are followed over time, confounding factors might have less influence on the overall outcome. In the current study, only patients who survived at least 1 year after HSCT were enrolled in the study. It remains unknown whether UA levels would also normalize in patients with worse outcomes.
In conclusion, HSCT is associated with significant changes in UA levels in patients with hematologic disorders.
Fig. 2. Changes in serum uric acid levels over time after hematopoietic stem cell transplantation.
Abbreviations: HSCT, hematopoietic stem cell transplantation; UA, uric acid; Q, quartile; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; MF, myelofibrosis; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; PNH, paroxysmal nocturnal hemoglobinuria; SAA, severe aplastic anemia; GS, granulocytic sarcoma.
Fig. 3. Correlation of post-transplant uric acid (UA) levels between HSCT recipients and respective donors. UA levels in 89 patients at 12 months after HSCT were correlated with levels of their corresponding graft donors. Correlations were compared using Pearson's coefficient.
Abbreviation: HSCT, hematopoietic stem cell transplantation.
Table 1 Demographics and baseline characteristics of patients undergoing hematopoietic stem cell transplantation.
Data are expressed as mean±SD for continuous variables and percentages for categorical variables.
- Hediger, MA, Johnson, RJ, Miyazaki, H, Endou, H. Molecular physiology of urate transport. Physiology (Bethesda), 2005;20;125-133.
- Kamble, RT, Guo, S, Ramos, CA, Carrum, G. Acute gout at engraftment following hematopoietic transplantation. Am J Hematol, 2011;86;961-962.
- Yamauchi, T, Negoro, E, Lee, S, et al. A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia. Anticancer Res, 2013;33;3947-3951.
- Carpenter, PA, Ziegler, JB, Vowels, MR. Late diagnosis and correction of purine nucleoside phosphorylase deficiency with allogeneic bone marrow transplantation. Bone Marrow Transplant, 1996;17;121-124.
- Zegers, BJ, Stoop, JW, Staal, GE, Wadman, SK. An approach to the restoration of T cell function in a purine nucleoside phosphorylase deficient patient. Ciba Found Symp, 1978;68;231-253.
- Cannell, PK, Herrmann, RP. Urate metabolism during bone marrow transplantation. Bone Marrow Transplant, 1992;10;337-339.
- Rieselbach, RE, Bentzel, CJ, Cotlove, E, Frei, E, Freireich, EJ. Uric acid excretion and renal function in the acute hyperuricemia of leukemia. Pathogenesis and therapy of uric acid nephropathy. Am J Med, 1964;37;872-883.
- Shulman, H, Striker, G, Deeg, HJ, Kennedy, M, Storb, R, Thomas, ED. Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury. N Engl J Med, 1981;305;1392-1395.
- Lin, HY, Rocher, LL, McQuillan, MA, Schmaltz, S, Palella, TD, Fox, IH. Cyclosporine-induced hyperuricemia and gout. N Engl J Med, 1989;321;287-292.
- da Silva, JB, de Melo Lima, MH, Secoli, SR. Influence of cyclosporine on the occurrence of nephrotoxicity after allogeneic hematopoietic stem cell transplantation: a systematic review. Rev Bras Hematol Hemoter, 2014;36;363-368.
PDF
Standard view
Export citation
Share Article
Original Article
Blood Res 2016; 51(3): 200-203
Published online September 23, 2016 https://doi.org/10.5045/br.2016.51.3.200
Copyright © The Korean Society of Hematology.
Changes in serum uric acid levels after allogeneic hematologic stem cell transplantation: A retrospective cohort study
Sang Hyun Joo1,#, Jin Kyun Park1,2,#, Eunyoung Emily Lee1, Yeong Wook Song1,2, and Sung-Soo Yoon3,4,5*
1Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
2Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Medical Research Institute, Seoul National University, Seoul, Korea.
3Division of Hematology and Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
4Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
5Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
Correspondence to:Correspondence to Sung-Soo Yoon, M.D., Ph.D. Division of Hematology/Oncology, Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Clinical Research Institute, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul 03080, Korea. ssysmc@snu.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background
Since cell turnover in the hematopoietic system constitutes a major source of uric acid (UA) production, we investigated whether hematopoietic stem cell transplantation (HSCT) is associated with significant changes in serum UA levels in patients with hematological disorders.
Methods
Patients who underwent HSCT at our institution between 2001 and 2012 were retrospectively enrolled. Serum UA levels at 3 months before, 1 week before, and 3 months and 1 year after HSCT were examined.
Results
Complete clinical and laboratory information including data regarding UA levels was available for 93 patients. At baseline, the mean UA level was 4.9±2.1 mg/dL, with an overall prevalence of hyperuricemia of 15% (defined as serum UA>6.8 mg/dL). Mean UA levels tended to be higher in patients with acute myeloid leukemia (4.8±2.0 mg/dL) and non-Hodgkin lymphoma (5.1±2.3 mg/dL) and lower in patients with aplastic anemia (mean, 4.2±1.8 mg/dL). UA levels dropped during myeloablative conditioning, reaching a nadir on the day of HSCT (3.27±1.4 mg/dL). Over the 3 months following HSCT, UA levels rose sharply (5.0±2.1 mg/dL) and remained stable up to 1 year after HSCT (5.5±1.6 mg/dL). UA levels in HSCT recipients at 12 months correlated with those of their respective graft donors (Pearson r=0.406,
Conclusion
HSCT is associated with significant changes in uric acid levels in patients with hematologic disorders.
Keywords: Uric acid, Hematopoietic stem cell transplantation, Bone marrow
INTRODUCTION
Degradation of purine nucleotides during cell turnover contributes to endogenous production of uric acid (UA). Constant turnover of hematopoietic cells constitutes a major site of purine salvage and metabolism [1]. With normal UA removal by the kidney, serum UA levels should correlate with cell turnover in the hematopoietic system. Accordingly, pathologically accelerated cell turnover in patients with hematologic malignancies would increase the delivery of purines to the liver where hepatic xanthine oxidase metabolizes them into UA, resulting in increased serum UA levels. Indeed, elevated UA levels in patients with acute myeloid leukemia (AML) are predictive of a poor outcome [2,3]. Conversely, a reduced cell turnover in bone marrow (BM) is associated with lower serum UA levels [4,5].
Successful hematopoietic stem cell transplantation (HSCT) restores blood cell turnover in BM. HSCT with associated radical changes may significantly affect serum UA levels and may even normalize levels in patients with hematological diseases. To date, the long-term effects of HSCT on serum UA levels have not been fully elucidated [6]. In this study, we aimed to investigate the changes in UA levels over time in patients who underwent allogeneic HSCT.
MATERIALS AND METHODS
The medical records of 292 patients who underwent allogeneic HSCT at Seoul National University Hospital between 2001 and 2012 were reviewed. Baseline clinical characteristics, BM pathology, karyotypes, and serum UA levels were ascertained by reviewing the electronic medical records. Within 1 year of HSCT, 117 patients died. Major causes of death were septic shock (N=42, 35.9%), graft-versus-host disease (N=25, 21.4%), and infection (N=19, 16.2%). Therefore, a comprehensive medical record was available in 93 patients (Fig. 1). Serum UA levels at day 90±14 before HSCT, on the day of transplantation, and at days 90±14 and 365±14 post-HSCT were examined. Of note, per the HSCT protocol at our institution, all patients received allopurinol 300 mg daily during myeloablative conditioning (i.e., 7 days before HSCT) as prophylaxis for tumor lysis syndrome. Patients also received cyclosporine as prophylaxis for graft-versus-host disease.
The study was approved by the Institutional Review Board of Seoul National University Hospital. Obtaining informed consent was waived by the Review Board as the study involved minimal risk and no identifiable information was used.
Data were expressed as mean±SD for continuous variables and percentages for categorical variables. Student's t-tests or the Mann-Whitney test for continuous variables was performed as appropriate. The changes in UA levels over time were evaluated using repeated measure analysis of variance (ANOVA). The correlation between recipient UA levels at 1 year after HSCT and donor UA levels were evaluated using Pearson's correlation.
RESULTS
Baseline characteristics of patients who underwent HSCT (N=93) are reported in Table 1. The mean age was 40.5±11.6 years. Acute myeloid leukemia (N=23) was the most common reason for HSCT, followed by severe aplastic anemia (N=15), acute lymphoblastic leukemia (N=15), and chronic myeloid leukemia (N=15). No patient had a prior history of gout.
The mean baseline UA level was 4.9±2.1 mg/dL. Similar baseline UA levels were observed in aplastic anemia patients (mean, 4.2±1.8 mg/dL). Mean UA levels tended to be higher in patients with chronic myeloid leukemia (6.4±2.0 mg/dL) and non-Hodgkin lymphoma (NHL, 5.1±2.3 mg/dL) (Fig. 2A). UA levels dropped significantly during myeloablative conditioning, reaching a nadir on the day of HSCT (3.3±1.4,
For 89 patients, UA levels of their respective hematopoietic stem cell donors were available. The UA levels in patients at 12 months after HSCT correlated significantly with those of their respective graft donors (Pearson's r=0.406,
DISCUSSION
To the best of our knowledge, this is the first report to demonstrate the changes in UA levels over time in patients who underwent allogeneic HSCT. Since the cell turnover in BM is a major contributor to endogenous production of UA, serum UA levels should closely correlate with cell turnover in the hematopoietic system. Indeed, baseline UA levels appeared to reflect cell turnover rate within and outside BM in patients with hematological diseases, with the lowest UA levels observed in patients with aplastic anemia and the highest in those with chronic myeloid leukemia (Fig. 2A). Higher UA levels might reflect increased pathological cell turnover; in fact, increased UA levels have been shown to be associated with a worse outcome in acute myeloid leukemia [3]. Conversely, lower UA levels might be associated with disease activity or a worse outcome in patients with aplastic anemia, which is characterized by hypocellular and possibly hypoactive BM. Accordingly, restoration of normal cell turnover after HSCT tended to normalize the serum UA levels; both elevated and decreased UA levels in recipients normalized at 1 year after HSCT (Fig. 2C). Of note, 235 (80.5%) of 292 patients underwent a follow-up BM study. Of those, 30 (12.8%) exhibited hypoplasia or aplasia, whereas 157 (66.8%) had normal BM. Disease recurred in 48 (20.4%) patients. UA levels tended to be different between patients with hypoplastic or aplastic BM (4.31±1.92 mg/dL), normal BM (4.76±2.13 mg/dL), and disease recurrence in BM (5.01±3.82 mg/dL) (data not shown). As to whether normalization of the serum UA level is a useful biomarker of successful long term engrafting needs to be investigated in a larger prospective cohort.
It is conceivable that the rate of cell turnover in the hematopoietic system varies around a preset individual baseline, depending on cell demand in the periphery [7]. HSCT replaces recipient BM cells with donor cells, and would reset the intrinsic cell turnover rate of the recipient to that of the donor. Indeed, UA levels of recipients correlated significantly with the baseline UA levels of the respective donors (Fig. 3).
This retrospective study has several limitations. The cell turnover in the hematopoietic system is only one of many factors contributing to serum UA levels [7,8]. UA levels are substantially influenced by the daily dietary intake, renal excretion, and concomitant medications that might influence cell turnover and renal function. As an example, a common immune suppressant, cyclosporine, which is routinely used to prevent graft-versus-host disease, can impair renal function and thus increase UA levels [8,9,10]. However, as UA levels of each patient are followed over time, confounding factors might have less influence on the overall outcome. In the current study, only patients who survived at least 1 year after HSCT were enrolled in the study. It remains unknown whether UA levels would also normalize in patients with worse outcomes.
In conclusion, HSCT is associated with significant changes in UA levels in patients with hematologic disorders.
Download
Fig 2.
Download
Changes in serum uric acid levels over time after hematopoietic stem cell transplantation.
Abbreviations: HSCT, hematopoietic stem cell transplantation; UA, uric acid; Q, quartile; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; MF, myelofibrosis; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; PNH, paroxysmal nocturnal hemoglobinuria; SAA, severe aplastic anemia; GS, granulocytic sarcoma.
Fig 3.
Download
Correlation of post-transplant uric acid (UA) levels between HSCT recipients and respective donors. UA levels in 89 patients at 12 months after HSCT were correlated with levels of their corresponding graft donors. Correlations were compared using Pearson's coefficient.
Abbreviation: HSCT, hematopoietic stem cell transplantation.
-
Table 1 . Demographics and baseline characteristics of patients undergoing hematopoietic stem cell transplantation..
Data are expressed as mean±SD for continuous variables and percentages for categorical variables..
References
- Hediger, MA, Johnson, RJ, Miyazaki, H, Endou, H. Molecular physiology of urate transport. Physiology (Bethesda), 2005;20;125-133.
- Kamble, RT, Guo, S, Ramos, CA, Carrum, G. Acute gout at engraftment following hematopoietic transplantation. Am J Hematol, 2011;86;961-962.
- Yamauchi, T, Negoro, E, Lee, S, et al. A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia. Anticancer Res, 2013;33;3947-3951.
- Carpenter, PA, Ziegler, JB, Vowels, MR. Late diagnosis and correction of purine nucleoside phosphorylase deficiency with allogeneic bone marrow transplantation. Bone Marrow Transplant, 1996;17;121-124.
- Zegers, BJ, Stoop, JW, Staal, GE, Wadman, SK. An approach to the restoration of T cell function in a purine nucleoside phosphorylase deficient patient. Ciba Found Symp, 1978;68;231-253.
- Cannell, PK, Herrmann, RP. Urate metabolism during bone marrow transplantation. Bone Marrow Transplant, 1992;10;337-339.
- Rieselbach, RE, Bentzel, CJ, Cotlove, E, Frei, E, Freireich, EJ. Uric acid excretion and renal function in the acute hyperuricemia of leukemia. Pathogenesis and therapy of uric acid nephropathy. Am J Med, 1964;37;872-883.
- Shulman, H, Striker, G, Deeg, HJ, Kennedy, M, Storb, R, Thomas, ED. Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury. N Engl J Med, 1981;305;1392-1395.
- Lin, HY, Rocher, LL, McQuillan, MA, Schmaltz, S, Palella, TD, Fox, IH. Cyclosporine-induced hyperuricemia and gout. N Engl J Med, 1989;321;287-292.
- da Silva, JB, de Melo Lima, MH, Secoli, SR. Influence of cyclosporine on the occurrence of nephrotoxicity after allogeneic hematopoietic stem cell transplantation: a systematic review. Rev Bras Hematol Hemoter, 2014;36;363-368.
Previous Article
Article Tools
Stats or Metrics
Share this article on
Related articles in BR
-
Peripheral T-cell lymphoma, NOS in bone marrow and heart
Hye Won Lee and Ja Young Lee
Blood Res 2024; 59(): -
Transfusion support in hematopoietic stem cell transplantation
Dong Wook Jekarl, Jae Kwon Kim, Jay Ho Han, Howon Lee, Jaeeun Yoo, Jihyang Lim, Yonggoo Kim
Blood Res 2023; 58(S1): S1-S7 -
Prognostic impact of total body irradiation dose in pediatric acute lymphoblastic leukemia patients treated with allogeneic hematopoietic stem cell transplantation in second complete remission
Wonjin Jang, Suejung Jo, Jae Won Yoo, Seongkoo Kim, Jae Wook Lee, Pil-Sang Jang, Nack-Gyun Chung, Bin Cho
Blood Res 2022; 57(4): 256-263
